patients receive the routine screening examination

patients receive the methylation markers screening

Cell-free DNA extraction from plasma samples-Bisulfite conversion of cfDNA-Determination of DNA methylation levels by deep sequencing-Sequencing data analysis

methylation markers screening

Hui-yan Luo, MD.PhD.

Rui-hua Xu, MD.PhD.

The purpose of this study is to evaluate the role of cell-free DNA methylation markers in cancer screening.

Cell-free DNA Methylation Markers for Cancer Screening

The proportion of persons with disease who have a positive test (positive test results among persons with disease)

The proportion of persons without disease who have a negative test (negative test results among persons without disease)

Sun Yat-sen University

Prof.

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Carcinoma

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Ovarian Cancer

Ovarian Epithelial Cancer

patients receive the ctDNA methylation markers screening

ctDNA extraction from plasma samples;bisulfite-treated DNA;DNA methylation levels by deep sequencing-Sequencing; data analysis

Yu Wang, M.D.

Epithelial ovarian cancer constitutes one of the most common gynecological malignancies.Because the ovaries lie in the deep pelvic cavity,most ovarian cancer patients are asymptomatic, rendering the majority often diagnosed at an advanced stage.ctDNA in cancer patients often bears similar genetic and epigenetic features to the related tumor DNA.This study aims to detect plasma ctDNA in Diagnosis of Epithelial Ovarian Cancer.

Epithelial ovarian cancer constitutes one of the most common gynecological malignancies, with an incidence rate of 3-12/100 000 woman per year. Because the ovaries lie in the deep pelvic cavity,most ovarian cancer patients are asymptomatic, rendering the majority often diagnosed at an advanced stage. Liquid biopsy, which is meant to detect cancers by sequencing the DNA in a few drops of a person's blood. It may detect cancers early, even before symptoms arise, when there is just a few cells in the blood circulation.

ctDNA in cancer patients often bears similar genetic and epigenetic features to the related tumor DNA. There is evidence that some of the ctDNA originates from tumor tissue. This, and the fact that ctDNA can easily be isolated from the circulation and other body fluids of patients, makes it a promising candidate as a non-invasive biomarker of cancer.

This study aims to detect plasma ctDNA in Diagnosis of Epithelial Ovarian Cancer.

Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.

Pathological diagnosis of ovarian lumps，including immunohistochemical information and HE staining information.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cell-free DNA Methylation Markers for Cancer Screening	NCT03096938	Cancer Screenin...	methylation mar...	40 Years - 74 Years	Sun Yat-sen University
Cell-free DNA Methylation Markers for Cancer Screening	NCT03096938	Cancer Screenin...	methylation mar...	40 Years - 74 Years	Sun Yat-sen University
Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.	NCT03155451	Epithelial Ovar...	methylation mar...	18 Years - 80 Years	RenJi Hospital
Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.	NCT03155451	Epithelial Ovar...	methylation mar...	18 Years - 80 Years	RenJi Hospital
Cell-free DNA Methylation Markers for Cancer Screening	NCT03096938	Cancer Screenin...	methylation mar...	40 Years - 74 Years	Sun Yat-sen University

Spots Global Cancer Trial Database for methylation markers screening